Perioperative medicine & outcomes
Association of remimazolam with delirium and cognitive function: A systematic review and meta-analysis of randomised controlled trials
Pooled result · Delirium incidenceResult — go to the resultOdds ratio 1.2 95% CI 0.76–1.91Authors' conclusion
Remimazolam does not increase the incidence of delirium or cognitive impairments compared with non-benzodiazepine hypnotics.
Study context
- Population
- Adults undergoing GA or sedation procedures
- Participants
- 3,598 adults · 23 RCTs
- Comparison
- Remimazolam vs other hypnotics or sedatives
- Outcome
- Delirium incidence
Pooled result
As reported in the abstract
Odds ratio
1.2
95% CI 0.76–1.91
P = 0.378843
Remimazolam vs Control
OR 1.2 (95% CI 0.76–1.91); P = 0.378843
Further pooled results
| Outcome | Mean difference (95% CI) | P value | |
|---|---|---|---|
| MMSE scores · first postoperative dayI2 = 90% | 0.60 (−1.46 to 2.66) | P = 0.5684 | |
| MMSE scores · third postoperative dayI2 = 93% | 1.33 (−0.72 to 3.38) | P = 0.2028 | |
| MMSE scores · seventh postoperative dayI2 = 28% | 0.53 (0.30–0.75) | P < 0.0001 | |
| −2024Difference (linear scale) |
- Mini-Mental State Examination (MMSE) scores: n = 263
- MMSE scores: n = 163
- MMSE scores: n = 247
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Association of remimazolam with delirium and cognitive function: A systematic review and meta-analysis of randomised controlled trials. Eur J Anaesthesiol. Published 18 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →